Joint adolescent–adult early phase clinical trials to improve access to new drugs for adolescents with cancer: proposals from the multi-stakeholder platform—ACCELERATE von Gaspar, N., Marshall, L.V., Binner, D., Herold, R., Rousseau, R., Blanc, P., Capdeville, R., Carleer, J., Copland, C., Kerloeguen, Y., Norga, K., Pacaud, L., Sevaux, M.-A., Spadoni, C., Sterba, J., Ligas, F., Taube, T., Uttenreuther-Fischer, M., Chioato, S., O'Connell, M.A., Geoerger, B., Blay, J.-Y., Soria, J.C., Kaye, S., Wulff, B., Brugières, L., Vassal, G., Pearson, A.D.J.

Volltext

Inclusion of adolescents in adult early phase trials and young adults in paediatric early phase trials: A reality or a myth? von Vozy, A., Berlanga Charriel, P., Geoerger, B., Massard, C., Gaspar, N.

Volltext

Larotrectinib efficacy and safety in TRK fusion cancer: An expanded clinical dataset showing consistency in an age and tumor agnostic approach von Tan, D.S.W., Lassen, U.N., Albert, C.M., Kummar, S., van Tilburg, C., Dubois, S.G., Geoerger, B., Mascarenhas, L., Federman, N., Basu-Mallick, A., Doz, F., Berlin, J.D., Oh, D.-Y., Bielack, S., McDermott, R., Cruickshank, S., Ku, N.C., Cox, M.C., Drilon, A., Hong, D.S.

Volltext

Larotrectinib efficacy and safety in TRK fusion cancer: An expanded clinical dataset showing consistency in an age and tumor agnostic approach von Lassen, U N, Albert, C M, Kummar, S, van Tilburg, C M, Dubois, S G, Geoerger, B, Mascarenhas, L, Federman, N, Schilder, R J, Doz, F, Berlin, J D, Oh, D-Y, Bielack, S S, McDermott, R, Tan, D S, Cruickshank, S, Ku, N C, Cox, M C, Drilon, A, Hong, D S

Volltext

277 INVITED IGF1R Targeting in Non-sarcoma Pediatric Malignancies von Geoerger, B

Volltext

Biomarker-driven access to crizotinib in ALK, MET or ROS1 positive (+) malignancies in adults and children: The French national AcSé program von Vassal, G, Cozic, N, Houot, R, Brugières, L, Aparicio, T, Blay, J-Y, Perol, M, Brice, P, Meriaux, E, Geoerger, B, El Bejjani, M R, Moalla, S, Bièche, I, Lantuejoul, S, Mahier Ait Oukhatar, C, Hoog Labouret, N, Moro-Sibilot, D

Volltext

Phase 1 study of ceritinib in pediatric patients with malignancies harboring activated anaplastic lymphoma kinase (ALK): Safety, pharmacokinetics and efficacy results from the fed... von Fischer, M, Wulff, B, Baruchel, S, Berlanga, P, Trahair, T, Mechinaud, F, Schulte, J, Modak, S, Merks, J.H, Zwaan, C.M, Marshall, L.V, Casanova, M, Branle, F, Malet, I, Emeremni, A.C, Geoerger, B

Volltext

A new approach to integrate toxicity grade and repeated treatment cycles in the analysis and reporting of phase I dose-finding trials von Doussau, A., Thiébaut, R., Geoerger, B., Schöffski, P., Floquet, A., Le Deley, M.C., Mathoulin-Pélissier, S., Rizzo, E., Fumoleau, P., Le Tourneau, C., Paoletti, X.

Volltext

347 Efficacy of Dasatinib in Targeting Diffuse Intrinsic Pontine Glioma (DIPG) Specific Pathway Activation in Vitro von Truffaux, N, Puget, S, Vassal, G, Geoerger, B, Grill, J

Volltext

Potentiation of radiation therapy by the oncolytic adenovirus dl1520 (ONYX-015) in human malignant glioma xenografts von Geoerger, B, Grill, J, Opolon, P, Morizet, J, Aubert, G, Lecluse, Y, van Beusechem, V W, Gerritsen, W R, Kirn, D H, Vassal, G

Volltext

Dose-finding designs in pediatric phase I clinical trials: Comparison by simulations in a realistic timeline framework von Doussau, A, Asselain, B, Le Deley, M.C, Geoerger, B, Doz, F, Vassal, G, Paoletti, X

Volltext

253 Anti-tumor Activity of the PLK Inhibitor Volasertib (BI 6727) and the Aurora Kinase Inhibitor BI 811283 in Pediatric Malignancies von Lanvers-Kaminsky, C, Abbou, S, Daudigeos-Dubus, E, Molenaar, J, Verschuur, A, Caron, H, Vassal, G, Geoerger, B

Volltext

9 INVITED Targeted therapies for paediatric brain tumours von Geoerger, B

Volltext

205 Development of Metastasis Following Inhibition of VEGFR Pathway in an Orthotopic Neuroblastoma Model von Daudigeos-Dubus, E, Le Dret, L, Philippe, C, Andreiuolo, F, Bawa, O, Pata-Merci, N, Munier, F, Vassal, G, Geoerger, B

Volltext

Enasidenib treatment in two individuals with D-2-hydroxyglutaric aciduria carrying a germline IDH2 mutation von Geoerger, Birgit, Schiff, Manuel, Penard-Lacronique, Virginie, Darin, Niklas, Saad, Selim-Maria, Duchon, Clarisse, Lamazière, Antonin, Desmons, Aurore, Pontoizeau, Clément, Berlanga, Pablo, Ducassou, Stéphane, Yen, Katharine, Su, Michael, Schenkein, David, Ottolenghi, Chris, De Botton, Stéphane

Volltext

Precision cancer medicine: Concepts, current practice, and future developments von Edsjö, Anders, Holmquist, Louise, Geoerger, Birgit, Nowak, Frédérique, Gomon, Georgy, Alix‐Panabières, Catherine, Staaf, Johan, Ploeger, Carolin, Lassen, Ulrik, Le Tourneau, Christophe, Lehtiö, Janne, Ott, Patrick A., von Deimling, Andreas, Fröhling, Stefan, Voest, Emile, Klauschen, Frederick, Dienstmann, Rodrigo, Alshibany, Aisha, Siu, Lillian L., Stenzinger, Albrecht

Volltext

627P Long-term efficacy and safety of larotrectinib in non-primary central nervous system (CNS) TRK fusion cancer von Drilon, A.E., Xu, R-H., van Tilburg, C.M., Doz, F., Tan, D.S.W., Lin, J.J., Geoerger, B., Zwaan, C.M., Lassen, U.N., Italiano, A., Kummar, S., McDermott, R.S., Burcoveanu, D-I., Neu, N., Brega, N., Laetsch, T., Hong, D.S., Shen, L.

Volltext

424P_PRInclusion of adolescents in adult early phase trials and young adults in paediatric early phase trials: A reality or a myth? von Vozy, A, Berlanga Charriel, P, Geoerger, B, Massard, C, Gaspar, N

Volltext

Phase I/II Platform Trial Design in pediatric cancer in relapse von Rossoni, C., Geoerger, B., Paoletti, X.

Volltext

463P Efficacy and safety of larotrectinib in a pooled analysis of patients (Pts) with tropomyosin receptor kinase (TRK) fusion cancer with an extended follow-up von McDermott, R.S., van Tilburg, C., Lin, J.J., Kummar, S., Tan, D.S.W., Albert, C.M., Berlin, J.D., Lassen, U.N., Doz, F., Geoerger, B., Mascarenhas, L., Federman, N., Norenberg, R., Dima, L., Mussi, C., De La Cuesta, E.A., Laetsch, T., Hong, D.S., Drilon, A.E.

Volltext